Medicine and Health

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

H. M. Colhoun, I. Lingvay, et al.

This study by authors including Helen M. Colhoun and Ildiko Lingvay reveals a promising potential of once-weekly semaglutide 2.4 mg to improve kidney outcomes in overweight and obese individuals without diabetes. With a significant reduction in the composite kidney endpoint, the findings offer a new perspective on kidney health in patients with cardiovascular disease.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

D. H. Ryan, I. Lingvay, et al.

Medicine and Health

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

D. H. Ryan, I. Lingvay, et al.

Medicine and Health

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

J. F. E. Mann, P. Rossing, et al.

Medicine and Health

Cardiovascular and autonomic dysfunction in long-COVID syndrome and the potential role of non-invasive therapeutic strategies on cardiovascular outcomes

G. Pérez-rubio, R. D. Rio, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny